FR2713087A1 - Use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis. - Google Patents
Use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis. Download PDFInfo
- Publication number
- FR2713087A1 FR2713087A1 FR9314299A FR9314299A FR2713087A1 FR 2713087 A1 FR2713087 A1 FR 2713087A1 FR 9314299 A FR9314299 A FR 9314299A FR 9314299 A FR9314299 A FR 9314299A FR 2713087 A1 FR2713087 A1 FR 2713087A1
- Authority
- FR
- France
- Prior art keywords
- selegiline
- treatment
- psoriasis
- derivatives
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 33
- 229960003946 selegiline Drugs 0.000 title claims abstract description 23
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 title claims abstract description 22
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 229960004310 piribedil Drugs 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000013066 combination product Substances 0.000 claims description 2
- 229940127555 combination product Drugs 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960001664 mometasone Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000073 effect on psoriasis Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne l'utilisation de la sélégiline et ses dérivés pour la préparation d'un médicament destiné au traitement du psoriasis.The present invention relates to the use of selegiline and its derivatives for the preparation of a medicament for the treatment of psoriasis.
Description
La présente invention concerne l'utilisation de la sélégiline et ses dérivés pour la préparation d'un médicament destiné au traitement du psoriasis. The present invention relates to the use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis.
Le psoriasis est une affection de la peau chronique et récurente. Les lésions apparaissent au niveau des articulations, genoux ou coudes, des extrémités ou du cuir chevelu. I1 évolue par poussées récurentes, liées générale- ment à des facteurs externes tels que les chocs, les infections ou les expositions aux UV. Le stress est également un facteur qui influence l'expression du psoriasis. Psoriasis is a chronic and recurring skin condition. The lesions appear at the joints, knees or elbows, extremities or scalp. It evolves by recurrent outbreaks, generally linked to external factors such as shocks, infections or exposure to UV rays. Stress is also a factor that influences the expression of psoriasis.
Les traitements usuels sont adaptés aux troubles de la kératinisation, en général par voie topique, notamment par des crèmes ou pommades kératolytiques, réductrices ou corticoïdes. The usual treatments are adapted to keratinization disorders, in general by the topical route, in particular by keratolytic, reducing or corticosteroid creams or ointments.
Ces traitements locaux peuvent être associés à des traitements généraux, notamment des rétinoïdes ou du methotrexate. These local treatments can be combined with general treatments, in particular retinoids or methotrexate.
I1 a été trouvé d'une manière inattendue que l'emploi de la sélégiline et ses dérivés connus par ailleurs pour le traitement de la maladie de Parkinson permettait d'améliorer l'état des patients atteints de psoriasis. It has been unexpectedly found that the use of selegiline and its derivatives known elsewhere for the treatment of Parkinson's disease makes it possible to improve the condition of patients suffering from psoriasis.
La présente invention concerne donc l'utilisation de la sélégiline et ses dérivés pour la préparation d'un médicament destiné au traitement du psoriasis. The present invention therefore relates to the use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis.
Par sélégiline et ses dérivés, on entend de préférence un composé de formule générale I, Ph-CH2-(CH(CH3))n-N(CH3)-CH2-CoCH pour laquelle Ph représente un groupe phényle et n est 1 ou O, ses sels d'ad- dition avec un acide thérapeutiquement acceptable, et le cas échéant ses énantiomères purs ou en mélange. By selegiline and its derivatives is preferably meant a compound of general formula I, Ph-CH2- (CH (CH3)) nN (CH3) -CH2-CoCH for which Ph represents a phenyl group and n is 1 or O, its addition salts with a therapeutically acceptable acid, and where appropriate its pure or mixed enantiomers.
D'une manière préférentielle, la présente invention concerne l'utilisation de la sélégiline, notamment son chlorhydrate. Preferably, the present invention relates to the use of selegiline, in particular its hydrochloride.
Le médicament obtenu et présenté sous une forme pharmaceutique appropriée à son administration, pour un traitement général ou local. The medicament obtained and presented in a pharmaceutical form suitable for its administration, for general or local treatment.
Pour un traitement général, le médicament obtenu sera de préférence sous une forme appropriée à son administration per os, notamment sous forme de comprimés, granulés, gélules ou poudres. For general treatment, the medicament obtained will preferably be in a form suitable for its administration per os, in particular in the form of tablets, granules, capsules or powders.
Pour un traitement local, le médicament obtenu sera de préférence présenté sous une forme appropriée pour une application topique, notamment sous forme de crème, de pommade, de gel ou d'émulsion. For local treatment, the drug obtained will preferably be presented in a form suitable for topical application, in particular in the form of cream, ointment, gel or emulsion.
Selon la formulation, les doses de sélégiline et ses dérivés sont comprises entre 0,5 et 5%, en poids par voie topique. Depending on the formulation, the doses of selegiline and its derivatives are between 0.5 and 5%, by weight topically.
Les doses de traitement pour des adultes de taille moyenne sont de environ 2 à 10 mg parjour par voie orale. Treatment doses for medium-sized adults are approximately 2 to 10 mg per day orally.
Le traitement pourra également être effectué en association avec d'autres médicanents usuels comme lepiribédil, les analogues de la vitamine D topique et/ou les corticostéroïdes topiques. The treatment may also be carried out in combination with other usual drugs such as lepiribedil, topical vitamin D analogs and / or topical corticosteroids.
La prise de ces différents produits peut bien entendu être simultanée séparée ou décalée dans le temps. The intake of these different products can of course be simultaneous separate or delayed in time.
La présente invention concerne donc également un nouveau produit comprenant la sélégiline et ses dérivés, tels que définis plus haut, et du piribédil, du calcipotriol et/ou de la mométasone comme produit de combinaison pour une utilisation simultanée, séparée ou étalée dans le temps pour le traitement du psoriasis. The present invention therefore also relates to a new product comprising selegiline and its derivatives, as defined above, and piribedil, calcipotriol and / or mometasone as a combination product for simultaneous, separate or spread over time use. the treatment of psoriasis.
Les résultats expérimentaux d'un traitement du psoriasis reporté cidessous montrent sans équivoque l'amélioration obtenue. The experimental results of a psoriasis treatment reported below show unequivocally the improvement obtained.
PATIENTS ET METHODES
22 patients (18 hommes et 4 femmes), atteints de psoriasis en plaques grave et rebelle à différents traitements, ont reçu la sélégiline après consentement informé écrit. Tous ces patients avaient bénéficié précédemment de la quasi-totalité des traitements disponibles : topiques, (goudrons, stéroïdes analogues de la vitamine D) et systémiques (PUVA, RE-PUVA, rétinoides, méthotrexate, cyclosporine A, salazopyrine). La réponse à ces différents traitements n'avait pas été satisfaisante et l'obtention d'un blanchiment total n'était pas habituelle ou pour des courtes périodes sous traitement majeur (méthotrexate, cyclosporine A), avec rechute rapide à l'arrêt. PATIENTS AND METHODS
22 patients (18 men and 4 women), suffering from severe plaque psoriasis and resistant to different treatments, received selegiline after written informed consent. All of these patients had previously benefited from almost all of the treatments available: topical (tar, steroid analogues of vitamin D) and systemic (PUVA, RE-PUVA, retinoids, methotrexate, cyclosporin A, salazopyrine). The response to these different treatments had not been satisfactory and obtaining total whitening was not usual or for short periods under major treatment (methotrexate, cyclosporine A), with rapid relapse when stopped.
les doses de sélégiline étaient de 5 mg - 1 jour sur 2- pendant 2 semaines puis 5 mg/jour pendant plusieurs mois à avaler lors du repas du matin. the selegiline doses were 5 mg - 1 every 2 days for 2 weeks then 5 mg / day for several months to be swallowed during the morning meal.
Le bilan biologique au début et lors de contrôles entre le 2ème et le 4ème mois du traitement comprenait: une numération formule sanguine, glycémie à jeun, sodium, potassium, urée, créatinine, phosphatases alcalines et transaminases plasmatiques. The biological assessment at the start and during checks between the 2nd and 4th month of treatment included: a blood count, fasting blood sugar, sodium, potassium, urea, creatinine, alkaline phosphatases and plasma transaminases.
Les résultats ont été appréciés sur la décroissance de la valeur du
PASI ("Psoriasis Area and Severity Index"). The results were assessed on the decrease in the value of the
PASI ("Psoriasis Area and Severity Index").
RESULTATS
1/ TOLERANCE
Le traitement a dû être interrompu chez quatre patients (18%, dont deux recevaient aussi du piribédil) au cours des premières semaines. Les symptômes étaient: agitation (3 patients), anxiété (1 patient), insomnie (1 patient), nausées et vomissements (1 patient), sécheresse de la muqueuse buccale accompagnée d'une mauvaise haleine (1 patient), et précordialgies (1 patient).RESULTS
1 / TOLERANCE
Treatment had to be stopped in four patients (18%, two of whom were also receiving piribedil) within the first few weeks. Symptoms were: restlessness (3 patients), anxiety (1 patient), insomnia (1 patient), nausea and vomiting (1 patient), dryness of the oral mucosa accompanied by bad breath (1 patient), and precordialgia (1 patient).
Dans tous les autres cas traités, la tolérance a été bonne et a permis une administration prolongée, en moyenne 6,1 mois, avec un total de 136 mois de traitement. Les examens sanguins n'ont montré aucune anomalie. In all the other cases treated, tolerance was good and allowed prolonged administration, on average 6.1 months, with a total of 136 months of treatment. The blood tests showed no abnormalities.
2/ SORTIES DE L'éTUDE
Deux patients ont décidé après acceptation initiale de ne pas prendre la sélégiline ; un autre a affirmé l'avoir pris pendant quelques semaines mais ne s'est présenté au contrôle que plusieurs semaines plus tard. 2 / OUTPUTS OF THE STUDY
Two patients decided after initial acceptance not to take selegiline; another claimed to have taken it for a few weeks but did not appear at the check-up until several weeks later.
3/ EFFET SUR LE PSORIASIS
Cas traités en gmonothérapie"
Quatre patients évaluables ont accepté de ne pas recevoir d'autre traitement que l'association sélégiline-piribédil, comme dans l'observation initiale. La valeur initiale du PASI était de 20,4 en moyenne (extrêmes: 15,4 25,1), la dernière valeur était en moyenne de 13,4 (extrêmes : 3,2 - 21,7), donc une amélioration moyenne de 35% (extrêmes: 15-79%). 3 / EFFECT ON PSORIASIS
Cases treated in gmonotherapy "
Four evaluable patients agreed to receive no treatment other than the combination selegiline-piribedil, as in the initial observation. The initial value of PASI was 20.4 on average (range: 15.4 25.1), the last value was average of 13.4 (range: 3.2 - 21.7), so an average improvement of 35% (range: 15-79%).
Le piribédil a été administré seulement au cours des 12 premiers mois du traitement, et son arrêt n'a pas amené de différence dans la réponse. Piribedil was administered only during the first 12 months of treatment, and its discontinuation made no difference in response.
Les patients ont tous noté une modification du psoriasis et observé que les plaques devenaient moins infiltrées, avec une nette augmentation de la desquamation en début de traitement. Ils ont aussi observé que l'évolution naturelle de leur maladie semblait s'être stabilisée; ceci explique la remarquable adhésion au traitement puisque la prise de sélégiline est très prolongée (durée supérieure à 13.7 mois). The patients all noted a change in psoriasis and observed that the plaques became less infiltrated, with a marked increase in scaling at the start of treatment. They also observed that the natural course of their disease appeared to have stabilized; this explains the remarkable adherence to the treatment since taking selegiline is very prolonged (duration greater than 13.7 months).
Cas traités en association
Ces observations initiales indiquaient que la sélégiline seule, sans piribédil, était susceptible de stabiliser l'évolutivité du psoriasis, sans amener un blanchiment suffisant de type cyclosporine ou méthotrexate.Cases treated in association
These initial observations indicated that selegiline alone, without piribedil, was capable of stabilizing the evolution of psoriasis, without bringing about sufficient bleaching of the cyclosporine or methotrexate type.
Une autre stratégie a donc été envisagée, comportant: - Une phase d'attaque avec sélégiline associé à des traitements locaux et si
nécessaires systémiques; cette phase était destinée à obtenir une améliora
tion maximum du psoriasis.Another strategy was therefore envisaged, comprising: - An attack phase with selegiline associated with local treatments and if
systemic kits; this phase was intended to obtain an improvement
maximum psoriasis.
- Une phase d'entretien, lors de laquelle la sélégiline est poursuivie alors que
les autres traitements sont progressivement diminués, voire stoppés.- A maintenance phase, during which selegiline is continued while
the other treatments are gradually reduced, even stopped.
L'évolution et la consommation des autres traitements servent alors de
critère d'évaluation.The evolution and consumption of other treatments then serve to
evaluation criteria.
L'évaluation des effets de la sélégiline dans un tel contexte pourrait paraître aléatoire. Cependant, tous les patients inclus étaient atteints de psoriasis grave, et suivis par la même équipe depuis des années. La réponse de leur maladie aux différents traitements était donc bien connue, ce qui permettait une évaluation adéquate dans le cadre d'une étude pilote. The evaluation of the effects of selegiline in such a context could seem random. However, all of the patients included had severe psoriasis, and had been followed by the same team for years. The response of their disease to the various treatments was therefore well known, which allowed an adequate evaluation within the framework of a pilot study.
Les patients qui ont reçu ce protocole thérapeutiquement ont remarquablement répondu. Patients who received this protocol therapeutically responded remarkably.
- Dans les dix cas traités par calcipotriol-mométasone-sélégiline, le blanchi
ment du psoriasis a été obtenu en un temps très court, et la rémission se
maintient depuis plusieurs mois sous sélégiline, avec une utilisation
minime de calcipotriol-mométasone hebdomadaire. Ce résultat est
considéré prr l'équipe soignante et les patients comme tout à fait inhabi
tuel. En effet, il s'agit de patients ayant nécessité précédemment des
thérapeutiques majeures (méthotrexate, cyclosporine) et dont le psoriasis
rechutait dès l'arrêt de celles-ci.- In the ten cases treated with calcipotriol-mometasone-selegiline, the bleached
psoriasis was obtained in a very short time, and the remission
maintains for several months on selegiline, with use
minimal weekly calcipotriol-mometasone. This result is
regarded by the healthcare team and the patients as completely uninhabited
tuel. Indeed, these are patients who previously required
major therapies (methotrexate, cyclosporine) and including psoriasis
relapsed as soon as they stopped.
- Dans les trois cas restants, le même effet potentialisateur de la sélégiline a
été observé.- In the three remaining cases, the same potentiating effect of selegiline a
been observed.
I1 s'agit donc d'une amélioration particulièrement inattendue, puisque aucun des traitements usuels n'avaient apporté à ce jour une solution appropriée pour ces différents patients. It is therefore a particularly unexpected improvement, since none of the usual treatments had to date provided an appropriate solution for these different patients.
Claims (7)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9314299A FR2713087B1 (en) | 1993-11-30 | 1993-11-30 | Use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis. |
| PCT/FR1994/001384 WO1995015160A1 (en) | 1993-11-30 | 1994-11-29 | Use of selegiline and its derivatives for the treatment of psoriasis |
| AU11924/95A AU1192495A (en) | 1993-11-30 | 1994-11-29 | Use of selegiline and its derivatives for the treatment of psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9314299A FR2713087B1 (en) | 1993-11-30 | 1993-11-30 | Use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2713087A1 true FR2713087A1 (en) | 1995-06-09 |
| FR2713087B1 FR2713087B1 (en) | 1996-02-23 |
Family
ID=9453358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9314299A Expired - Fee Related FR2713087B1 (en) | 1993-11-30 | 1993-11-30 | Use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis. |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU1192495A (en) |
| FR (1) | FR2713087B1 (en) |
| WO (1) | WO1995015160A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU223475B1 (en) * | 1994-10-24 | 2004-07-28 | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. | Liposome composition comprising selegiline and a method for producing it |
| AU750909B2 (en) | 1998-03-16 | 2002-08-01 | Somerset Pharmaceuticals, Inc. | Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992021333A2 (en) * | 1991-05-24 | 1992-12-10 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
-
1993
- 1993-11-30 FR FR9314299A patent/FR2713087B1/en not_active Expired - Fee Related
-
1994
- 1994-11-29 AU AU11924/95A patent/AU1192495A/en not_active Abandoned
- 1994-11-29 WO PCT/FR1994/001384 patent/WO1995015160A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992021333A2 (en) * | 1991-05-24 | 1992-12-10 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
Non-Patent Citations (3)
| Title |
|---|
| G. IONESCU ET AL.: "Monoamine-and diamine oxidase activities in psoriasis.", ACTA DERMATO-VENEREOL., vol. 69, no. 3, 1989, pages 264 - 265 * |
| M.A. GUPTA ET AL.: "Psychotropic drugs in dermatology.", J. AM. ACAD. DERMATOL., vol. 14, no. 4, 1986, pages 633 - 645 * |
| T. DI PRIMA ET AL.: "IMAO in the treatment of psoriasis vulgaris.", G. ITAL. DERMATOL. VENEREOL., vol. 124, no. 9, 1989, pages 419 - 420 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2713087B1 (en) | 1996-02-23 |
| WO1995015160A1 (en) | 1995-06-08 |
| AU1192495A (en) | 1995-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU765749B2 (en) | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein | |
| US5977087A (en) | Topical preparation for treatment of aphthous ulcers and other lesions | |
| EP2170349B1 (en) | Treatment of heart deficiency in non-human mammals with an aldosterone antagonist | |
| CA2220677A1 (en) | Endothelin antagonists and endothelin synthase inhibitors for the prevention and treatment of uterine contractility disorders, preeclampsia, atherosclerotic vascular disease, hypertension and for hormone replacement therapy | |
| CA1328621C (en) | Galenic forms of beta-2-mimetics for per- and sublingual administration | |
| FR2629716A1 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION BASED ON DIPHOSPHONIC ACID DERIVATIVE | |
| EP0527757B1 (en) | Composition and methods for treatment of acne vulgaris and retardation of ageing | |
| BE897355A (en) | ANALGESTIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING IBUPROFEN | |
| FR2530469A1 (en) | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITION CONTAINING CAFFEINE | |
| EP1102586A1 (en) | Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis | |
| HU228051B1 (en) | A pharmaceutical composition for the treatment of autoimmune diseases | |
| WO1999053914A1 (en) | Remedies for primary biliary cirrhosis | |
| FR2713087A1 (en) | Use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis. | |
| FR2749511A1 (en) | COSMETIC METHOD OF TREATMENT AND PREVENTION OF SIGNS OF AGING SKIN | |
| EP2288342B1 (en) | Magnesium system and use thereof in the cosmetics industry | |
| US7323471B1 (en) | Topical azathioprine for the treatment of oral autoimmune diseases | |
| FR2727629A1 (en) | OSTEOPOROSIS TREATMENT CYCLE KIT | |
| JP3177686B2 (en) | Dysmenorrhea prevention or treatment agent and dysmenorrhea prevention functional food | |
| JPH03127734A (en) | Benfotiamine preparation | |
| EP0968717B1 (en) | Galenic formulatin for reducing effects induced during or after menopause and method of treatment using same | |
| WO2005034972A2 (en) | Use of pharmaceutical compositions containing evening primrose oil for the treatment of xerostomia | |
| BE829197A (en) | ANTI-INFLAMMATORY COMPOSITIONS, THEIR PREPARATION AND THEIR USE | |
| LU86290A1 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON 3-AMINOPROPOXYINDOLES | |
| US20070155786A1 (en) | Methods for treating oral aphthous stomatitis and oral mucositis | |
| BE894110A (en) | USE OF TRAZODONE IN THE TREATMENT OF GASTROINTESTINAL ULCERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |
Effective date: 20130731 |